Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

Thrombosis and COVID-19: Controversies and (Tentative) Conclusions

9 Feb, 2021 | 01:41h | UTC

Thrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases

 

Commentary on Twitter

 


Small RCT: Peginterferon lambda increases viral clearance in outpatients with COVID-19

9 Feb, 2021 | 01:36h | UTC

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial – The Lancet Respiratory Medicine

 


Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy

7 Feb, 2021 | 20:55h | UTC

Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)

Audio Clinical Review: Management of Immunotherapy-Related Toxicities

Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities

 


Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack

7 Feb, 2021 | 20:54h | UTC

Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study – The BMJ

See calculator: Canadian TIA Score

 

Commentary on Twitter

 


What’s the risk of dying from a fast-spreading COVID-19 variant?

7 Feb, 2021 | 21:21h | UTC

What’s the risk of dying from a fast-spreading COVID-19 variant? – Nature

Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv

 


Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19

7 Feb, 2021 | 21:13h | UTC

“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia

 


Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension

4 Feb, 2021 | 01:18h | UTC

Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension (LTH-1): A multicenter randomized controlled trial – EClinicalMedicine

 

Commentary on Twitter

 


German 2021 guideline update on acute therapy and management of anaphylaxis

4 Feb, 2021 | 01:17h | UTC

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update – Allergo Journal International

 


RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

4 Feb, 2021 | 01:39h | UTC

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet

 


[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials

1 Feb, 2021 | 01:58h | UTC

Full-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)

Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial

News release: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.